Review Article

Technological Advancement in Drug Development:
Pharmacogenomics Based Precision Medicine

Anjana T K*,[1] Dr. Kinjal Bipinkumar Gandhi [2]

1. ORCID ID: 0009-0003-3731-9883
   Post Graduate Scholar, Department of Pharmaceutical Regulatory Affairs, Chemists College of Pharmaceutical Sciences & Research (Affiliated with Kerala University of Health Sciences, Thrissur), Varikoli P.O., Puthencruz, Ernakulam 682308, Kerala, India.
2. Professor, Department of Pharmaceutics, Chemists College of Pharmaceutical Sciences & Research (Affiliated with Kerala University of Health Sciences, Thrissur), Varikoli P.O., Puthencruz, Ernakulam 682308, Kerala, India.
   *Corresponding author's E-mail: anjanatk121@gmail.com

ABSTRACT

Technological advancements, particularly pharmacogenomics, have revolutionized drug development by tailoring treatments to individual genetic profiles. This precision medicine approach enhances therapeutic efficacy, minimizes adverse reactions, and personalizes patient care. Integrating genetic information into treatment plans marks a significant shift towards more effective and individualized healthcare. Innovations such as high-throughput screening, genomic sequencing, and AI have significantly accelerated drug development by enabling precise identification of potential drug candidates and optimizing clinical trials, thus reducing time and cost. Pharmacogenomics leverages genetic information to tailor treatments, enhancing efficacy and minimizing adverse reactions. Together, these innovations promise to deliver more effective, safer, and personalized treatments, improving patient outcomes and revolutionizing healthcare. However, challenges in pharmacogenomics-based precision medicine include the complexity of genetic data interpretation, the need for changes in clinical practice infrastructure, high costs, and data privacy concerns. Limitations involve incomplete genetic knowledge, variability in testing methods, and the need for diverse population research. Addressing these challenges is crucial for the successful implementation of personalized treatments, ultimately enhancing therapeutic efficacy and safety, and advancing patient-centered healthcare. The potential of pharmacogenomics-based precision medicine to revolutionize drug development and improve patient outcomes highlights its critical importance in the future of healthcare.

Keywords: Pharmaco-genomics, precision medicine, drug development, oncology.

INTRODUCTION

The landscape of drug development is rapidly evolving, driven by significant technological advancements and shifting industry dynamics.[7] The process of bringing a new drug to market is complex, time-consuming, and costly, often taking over a decade and exceeding $2 billion in expenses. [8] Key challenges include rising clinical trial costs, complex protocol designs, and patient recruitment issues.[9] Despite these hurdles, the industry is witnessing a transformative shift towards more efficient and innovative approaches. Transformative Role of Technology includes Artificial Intelligence (AI), Genomic Sequencing, High-Throughput Screening, Decentralized Clinical Trials.[10] These technological advancements are transforming the drug development landscape, making it more efficient, cost-effective, and patient-centered. By leveraging AI, genomic sequencing, high-throughput screening, and decentralized trials, the industry is poised to deliver more personalized and effective treatments, ultimately improving patient outcomes and revolutionizing healthcare.

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs.[11] This field combines principles of pharmacology and genomics to understand how genetic variations affect drug metabolism, efficacy, and safety. Pharmacogenomics, often used interchangeably with pharmacogenetics, is a crucial aspect of precision medicine that is increasingly utilized in clinical practice to optimize medication therapy, especially in oncology.[11] While precision medicine is frequently associated with genomics, it encompasses the use of various clinical variables to personalize medication selection and dosing. Since the Human Genome Project, there has been significant interest in how genetics and genomics will influence drug research.[12] For future success in research and development, it is essential to incorporate novel therapeutic concepts and drug targets using customized digital technologies and patient-centered drug development.[13] These elements contribute to a broader shift from one-size-fits-all medicine to precision medicine (PM), which aims to provide the right medicine for the right patient at the correct dose and time.[2] PM signifies a new chapter in genetics and drug discovery. [14]

Integrating genetic information into drug development and treatment plans is of paramount importance for several reasons such as Personalized Treatment, Minimizing Adverse Reactions, Optimizing Drug Dosing, Improving Drug Development, Reducing Trial-and-Error, and Advancing Precision Medicine.[15] By leveraging genetic information, the healthcare industry can deliver more effective, safer, and personalized treatments, marking a significant advancement in the field of medicine.[16]

Due to its origin from genetic abnormalities, cancer has emerged as one of the fastest-growing fields for the clinical application of pharmacogenomics.[17] It allows for the customization of cancer treatments based on an individual's genetic profile.[18] Precision medicine involves tailoring treatments to the specific genetic mutations and molecular characteristics of a patient's tumor.[19] The integration of pharmacogenomics into drug development accelerates the discovery of new cancer therapies.[14] In summary, pharmacogenomics and precision medicine have transformed oncology by providing personalized, targeted, and safer cancer treatments.[16]

The primary objective of this review article is to examine the intersection of technological advancements and pharmacogenomics in drug development. Specifically, the article aims to Investigate Technological Innovations, Analyse Pharmacogenomics, Highlight Clinical Applications, Discuss Challenges and Ethical Considerations, Forecast Future Directions, and importance in cancer treatment. By achieving these objectives, the article aims to provide a comprehensive understanding of how technological advancements and pharmacogenomics are transforming drug development and paving the way for more personalized and effective medical treatments.[17]

Drug development: an overview

Drug development is a comprehensive and multi-phased process that aims to bring new pharmaceuticals to market.[20] It begins with the discovery phase, where researchers identify potential drug candidates through various methods such as high-throughput screening and rational drug design.[21] These candidates undergo preclinical testing in laboratories and on animal models to assess their safety and efficacy.[22] Promising compounds move on to clinical trials, which are conducted in multiple phases (Phase I, II, and III) to evaluate safety, dosage, and effectiveness in human volunteers.[23] Upon successful completion of clinical trials, a regulatory submission is made to agencies like the FDA or EMA for approval.[24] Post-approval, the drug is monitored continuously in the market for long-term safety and effectiveness.[24] The entire process, spanning over a decade and involving substantial financial investment, ensures that new drugs meet rigorous scientific and regulatory standards before reaching patients.[8]

What is pharmacogenomics

Pharmacogenomics, a subdivision of pharmacology, examines how genetic differences affect patients' responses to medications by linking gene expression or single-nucleotide polymorphisms to a drug's effectiveness or potential side effects.[11]

Pharmacogenomics examines how an individual's genetic makeup influences their response to drugs.[18] The term merges pharmacology and genomics, signifying the intersection of pharmaceutical science and genetics.[16] The field holds the promise that drugs can eventually be customized for individuals, tailored to each person's genetic profile.[2] While environment, diet, age, lifestyle, and overall health can all impact drug responses, understanding a person's genetic makeup is seen as crucial for developing personalized medications with greater efficacy and safety.[4] Drug response, encompassing both positive and negative reactions, is a complex trait affected by multiple genes.[25] Initially, the lack of comprehensive knowledge about all genes involved made it challenging to create genetic tests predicting individual drug responses.[26] However, with the discovery of small variations in people's genes, particularly in their nucleotide (DNA base) sequences, genetic testing for drug response prediction has become feasible.[27] Pharmacogenomics integrates traditional pharmaceutical sciences like biochemistry with in-depth knowledge of genes, proteins, and single nucleotide polymorphisms (SNPs), which are the most common variations in the human genome.[28] These tests can help determine if a drug will be effective or if it could cause side effects.[1] Pharmacogenomics can also help identify the best dose of a drug to prevent adverse reactions.[29]

Pharmacogenomics: origin and development

The concept of "pharmacogenetics," introduced by American geneticist Arno Moltulsky over fifty years ago, suggested that genetic inheritance could influence drug response.[30] Key early contributors included Werner Kalow and David Price Evans, who studied genetic variations affecting drug metabolism.[30] Discoveries in thiopurine S-methyltransferase (TPMT) and cytochrome P-450 (CYP) 2D6 highlighted genetic influences on drug efficacy and adverse reactions.[30] These foundational studies set the stage for systematic efforts to identify genetic variations affecting drug response, mainly focusing on pharmacokinetics (PK).[30]

During the late 1980s and 1990s, pharmacogenomic research involved cloning and sequencing genes related to drug response, revealing that much genetic variation resulted from common sequence variations in drug-metabolizing enzymes.[30] This progress is exemplified by the US FDA's list of drugs with pharmacogenomic biomarkers, highlighting the importance of making this knowledge accessible to practitioners.[30] Public-private collaborations, such as the NIH-funded Pharmacogenomics Research Network (PGRN) and eMERGE grants, have greatly stimulated pharmacogenomic discovery and clinical implementation.[30]

Overall, pharmacogenomics has advanced alongside genomic science, marking significant progress in identifying, characterizing, and determining the clinical utility of pharmacogenomic variants.[26]

Role of pharmacogenomics in drug development

Pharmacogenomics, which explores how genes influence an individual's drug response, plays a critical role in modern drug discovery and development.[26] By analysing genetic variations that impact drug metabolism, efficacy, and toxicity, pharmacogenomics facilitates the creation of personalized therapies that enhance patient outcomes and reduce adverse effects.[28] In drug discovery, insights from pharmacogenomics can identify genetic markers linked to

drug response, helping researchers select candidate compounds with greater efficacy and lower toxicity for specific populations.[4] In drug development, pharmacogenomic data guides clinical trial design by stratifying patient groups based on genetic profiles and predicting drug interactions.[31] figure 1 illustrates the role of pharmacogenomics from drug discovery to development. This customized approach lowers the likelihood of trial failures, accelerates the regulatory approval process, and leads to the creation of more targeted and effective medications.[32] As precision medicine becomes increasingly important, pharmacogenomics continues to influence the future of safe and effective therapeutics.[2]

Variation in drug response within a disease is typically attributed to multiple genes rather than a single gene mutation.[25] Genetic profiling allows researchers to identify individuals likely to respond well to treatment or those at risk for adverse reactions.[26] This approach enhances patient safety and increases the statistical power of trials by focusing on participants with relevant genetic backgrounds, thereby requiring fewer participants for meaningful results.[31] Pharmacogenomics facilitates adaptive trial designs, enabling real-time adjustments based on genetic responses, speeding up drug development and reducing costs.[33]

The complexity of human genetics poses challenges, as not all genetic variations are well understood, and their interactions can be intricate.[12] Nonetheless, pharmacogenomics, as a cornerstone of precision medicine, holds the potential to revolutionize healthcare by

offering individualized therapies that maximize benefits and minimize risks.[2] Integrating pharmacogenomics into drug discovery and development improves patient care and drives innovation in the pharmaceutical industry.[26,4]

Incorporating genetic testing into clinical trials has become standard practice, ensuring safer and more precise studies.[31] Figure 2 illustrate application of pharmacogenomics in each stage of drug development. Researchers can stratify participants based on their genetic profiles, accurately evaluating the drug's effectiveness and safety within specific genetic subgroups.[32] Pharmacogenomics, the study of how genetic differences affect individual drug responses, is vital in personalized medicine.[26] By identifying genetic markers linked to drug metabolism, efficacy, and potential side effects, pharmacogenomics allows healthcare providers to select the most effective medications and optimal dosages, reducing trial and error.[4]

Genetic testing can determine whether a patient will metabolize certain drugs, such as anticoagulants or antidepressants, too quickly or too slowly, informing appropriate dose adjustments to avoid toxicity or lack of efficacy.[30] Pharmacogenomics is also applied in managing adverse drug reactions.[34] In oncology, pharmacogenomic testing helps match patients with specific genetic mutations to targeted therapies, increasing treatment success rates.[35] As pharmacogenomic knowledge expands, its applications in drug discovery, development, and clinical practice will continue to grow.[26]


**Figure 1:** Role of pharmacogenomics in drug development

Figure 2: Application of pharmacogenomics in each stage of drug development.

Benefits of pharmacogenomics

More potent medications: Pharmaceutical companies will have the capability to create drugs based on proteins, enzymes, and RNA molecules linked to genes and diseases. This will streamline drug discovery and enable the production of therapies specifically targeted to particular diseases. Such precision will maximize therapeutic effects while minimizing damage to nearby healthy cells.[36]

Better, safer drugs from the start: Instead of relying on the traditional trial-and-error approach to find the right medications for patients, doctors will be able to analyse a patient's genetic profile and prescribe the most effective drug therapy right from the beginning.[26] This not only removes the uncertainty in selecting the right drug but also accelerates recovery and increases safety by minimizing the likelihood of adverse reactions.[4]

More accurate methods for determining drug dosages: Instead of relying on current methods that base dosages on weight and age, future approaches will consider a person's genetic profile.[25] Dosages will be tailored according to how well an individual's body processes the medication and the time it takes to metabolize it.[28] This will enhance the therapy's effectiveness and reduce the risk of overdose.[31]

Advanced disease screening: Understanding one's genetic code enables individuals to make lifestyle and environmental adjustments early in life to prevent or mitigate the severity of genetic diseases.[36] Additionally, knowing one's susceptibility to specific diseases allows for vigilant monitoring and the timely introduction of treatments at the most effective stages, optimizing therapeutic outcomes.[36]

Improved vaccines: Vaccines made from genetic material, either DNA or RNA, offer all the benefits of traditional vaccines without the associated risks.[36] They will trigger the immune system without causing infections, be cost-effective, stable, easy to store, and designed to carry multiple strains of a pathogen simultaneously.[36]

Enhancements in the drug discovery and approval process: Pharmaceutical companies will more easily discover potential therapies using genome targets. The drug approval process will be streamlined by targeting trials for specific genetic population groups, resulting in greater success rates. By focusing only on individuals likely to respond to a drug, the cost and risk of clinical trials will be significantly reduced.[36]

Reduction in overall healthcare costs: Lowering the number of adverse drug reactions, reducing the number of failed drug trials, shortening the time required to get a drug approved, decreasing the duration patients need to stay on medication, minimizing the number of medications required to find an effective therapy, early detection of diseases, and expanding the range of potential drug targets will collectively contribute to a significant decrease in healthcare costs.[36]

Obstacles to the advancement of pharmacogenomics.

Complexity of Identifying Gene Variations Affecting Drug Response

Single nucleotide polymorphisms (SNPs) are DNA sequence variations occurring when a single nucleotide (A, T, C, or G) in the genome is altered. SNPs appear every 100 to 300 bases along the 3-billion-base human genome, meaning millions of SNPs must be identified and analysed to determine their involvement in drug response.[36] This process is further complicated by our limited knowledge of which genes are involved in each drug response.[36] Since many genes are likely to influence drug responses, obtaining a comprehensive understanding of the impact of gene variations is both time-consuming and complex.[36]

Limited Drug Alternatives

For some conditions, only one or two approved drugs may be available. If patients possess gene variations that prevent them from using these drugs, they may be left without any treatment alternatives.[36]

Disincentives for Pharmaceutical Companies

Most pharmaceutical companies have thrived with a 'one size fits all' approach to drug development.[36] Given that bringing a drug to market costs hundreds of millions of dollars, these companies may be reluctant to develop alternative drugs that cater only to a small portion of the population.[36]

Future Perspectives and Opportunities in Pharmacogenomics

Integration of PGx Data in Drug Discovery and Development Pipelines:

Advances in gene expression, epigenomics, metabolomics, and proteomics help understand the molecular basis of diseases, impacting drug discovery and development.[37] Genetic tools identify new drug targets and provide insights during the early phases of drug discovery.[38] Clinical trials at various stages use pharmacogenomics (PGx) to stratify populations.[32] For example, the development of a nicotinamide phosphoribosyl transferase inhibitor for treatment-resistant prostate cancer illustrates the effectiveness of a PGx data-driven approach.[39] PGx data address critical questions of toxicity and efficacy, saving resources and time.[31] It screens drug compounds and identifies potential adverse reactions in preclinical drug design.[40] Pharmacogenetics isolates non-metabolizer patient groups and enhances drug development, fundamentally advancing medical practices.[28]

The Potential Impact of PGx on Precision Medicine and Healthcare Outcomes:

The shift from a one-size-fits-all approach to personalized treatment has led to significant improvements in healthcare delivery and therapeutics.[2] Achieving precision therapy requires data collection through medical diagnosis, individual therapy analysis, and appropriate business

designs.[41] Digital and mobile medical applications play a crucial role in characterizing disease in precision health.[42] Healthcare considers other information beyond genomics to predict disease risk and treatment outcomes.[43] PGx testing is already used to select and dose cardiovascular and psychiatry therapeutic agents and to identify predictive and prognostic biomarkers in cancer treatment.[26] It improves therapy efficacy, minimizes toxicity risk, and determines therapy responses in rheumatoid arthritis patients.[44] PGx significantly impacts drug prescription and dosing, playing a vital role in achieving personalized medicine for many diseases.[4]

Precision medicine

Precision medicine, also known as personalized medicine, is an innovative approach to healthcare that takes individual variability in genes, environment, and lifestyle into account for each person.[2] This method enables doctors and researchers to more accurately predict which treatment and prevention strategies will be effective for specific groups of people, in contrast to the one-size-fits-all approach, which focuses on the average person with less regard for individual differences.[41] Most medical treatments are designed for the average patient, which works for most but not all.[31] Individualized therapeutics, on the other hand, are tailored to treat one or a few individuals, addressing specific unmet health needs.[45] These therapies have become more achievable due to our enhanced understanding of individual variability and the identification of new rare genetic diseases through next-generation sequencing (NGS) technologies.[46]

One of the main challenges for precision medicine is determining the underlying mechanisms behind adverse events, such as why the body has a negative reaction to a treatment (e.g., developing a rash) and understanding the variations in efficacy (e.g., why a drug is more effective in some patients than others).[47]

While the term "precision medicine" is relatively new, the concept has been part of healthcare for many years.[14] For instance, when a person needs a blood transfusion, the donor's blood type is matched to the recipient to reduce the risk of complications, rather than using a randomly selected donor. Although examples of precision medicine can be found in several areas of medicine, its role in everyday healthcare is still limited.[48] However, researchers hope this approach will expand to many areas of health and healthcare in the coming years.[49] Another example is Bacteriophage (phage) therapy, which involves using viruses to invade and destroy bacterial cells, is being explored as an innovative antimicrobial method to treat antibiotic-resistant bacterial infections.[50] To counteract bacterial resistance to conventional antibiotics, personalized bacteriophage cocktails are tailored to target the patient's specific bacterial strain.[51] The FDA is developing and evaluating animal models to determine the safety and effectiveness of these bacteriophage cocktails in treating antibiotic-resistant infections.[52]

The goal of precision medicine is to target the right treatments to the right patients at the right time.[48] Progress in precision medicine has resulted in significant new discoveries and FDA-approved treatments tailored to individual characteristics, such as a person's genetic makeup or the genetic profile of a tumor.[49] Patients with various cancers frequently undergo molecular testing as part of their care, allowing physicians to choose treatments that enhance survival rates and minimize adverse effects.[53]

Evolution and significance of precision medicine

"personalized medicine" is an older term with a meaning close to "precision medicine".[45] The term first appeared in published works in 1999, though some core concepts of the field have existed since the early 1960s.[54] While the terms are often used interchangeably, there is a conceptual distinction between personalized medicine and precision medicine that refers to different approaches to patient care.[55] Hippocrates introduced the concept of personalized medicine thousands of years ago, emphasizing the individuality of disease and the necessity of providing different drugs to different patients.

Personalized medicine generally refers to medical treatments tailored to individual patients' needs, involving the use of genetic and epigenetic information, as well as considering their preferences, beliefs, attitudes, knowledge, and social contexts.[56] This approach relies on new technologies and individuals' unique molecular profiles to understand disease vulnerabilities.[14]

With the progress in research and clinical care, policies enabling personalized medicine have transformed the healthcare system. Collaborative networks among medical centers and highly qualified specialists equipped with precise tools can develop targeted therapy protocols for patient groups that traditional health systems have failed.[48] This has improved our ability to predict which medical treatments will be safe and effective for each patient, minimizing harmful side effects and ensuring more successful outcomes, while also containing costs compared to a "trial-and-error" approach.[57]

One major limitation of standard medical treatment is that it is designed for the "average patient," assuming that all patients with the same symptoms share a common patho-phenotype and should be treated similarly.[31] This "one-size-fits-all" approach can be very successful for some patients but not for others.[45]

Although the term precision medicine has gained popularity recently due to scientific and political initiatives, the concept has been part of healthcare for many years.[58] The President's Council of Advisors on Science and Technology, in a report from September 2008, specified that personalized medicine does not literally mean creating unique drugs or medical devices for each patient, but rather classifying individuals into subpopulations based on their susceptibility to diseases or response to specific treatments.[58] In January 2015, President Barak Obama launched the Precision Medicine Initiative, exposing the

general population to the broader concept of precision medicine as a bold effort to revolutionize healthcare and improve people's lives.[49]

Precision medicine focuses on identifying optimal care based on unique personal profiles, including genetics, exposures, lifestyle, and health factors, to determine disease susceptibility, understand the clinical course of the disease, and prescribe appropriate treatments for defined subpopulations of patients, rather than the average population.[55] The expansion of precision medicine relies on multiple sources from genomics, biological data, transcriptomics, and proteomics to be more precise and accurate in diagnosing and treating disease subtypes.[2] Prominent examples include cystic fibrosis and cancer.[19]

The discovery of biomarkers before the emergence of overt clinical symptoms and technological development have paved the way for rapid genomic discovery, transforming healthcare from a focus on precision medicine to a broader focus on precision health.[43] This offers the possibility of preventing disease altogether.[41] The future of precision medicine will enable healthcare providers to tailor treatment and prevention strategies to people's unique characteristics, including their genome sequence, microbiome composition, health history, lifestyle, and diet.[48]

Principles of Precision Medicine

The advent of precision medicine represents a paradigm shift from the conventional wisdom that illness treatment should be based on population averages to a highly personalized and focused approach.[2] This transition has led to significant changes in the healthcare industry. Precision medicine is founded on a set of fundamental principles that guide its operations and form the basis of its concepts.[55] The core premise of precision medicine is recognizing the inherent genetic diversity among individuals.[14] Each person has unique genetic characteristics that can greatly influence their reactions to diseases and treatments. Acknowledging the uniqueness of each individual's genetic composition at the cellular, molecular, and genetic levels is central to precision medicine.[41]

Precision medicine takes into account not only genetics but also the intricate web of molecular interactions and cellular pathways that underpin health and disease.[2] A thorough understanding of these complex processes is essential for tailoring treatments to each person's specific biological milieu.[59]

Recent advances in biotechnology, particularly in high-throughput sequencing, have made it possible to quickly and accurately understand the intricate genetic and molecular components of an individual's biology.[60] Collecting comprehensive genetic and molecular data using state-of-the-art technologies and data analysis is a key principle of precision medicine.[2] Given that each person's genetic and molecular composition is different, precision medicine acknowledges that the same disease may manifest differently in different individuals.[14] The personalization of

treatment is another fundamental concept, stating that therapeutic procedures should be adjusted to account for individual differences.[55]

This section will explore these principles in detail, examining their practical applications, healthcare implications, and groundbreaking impact on disease detection, treatment, and prevention.[41] The emergence of precision medicine marks a turning point in medical history, shifting the focus from merely treating symptoms to developing a complete understanding of each patient.[48] Ultimately, it aims to enhance healthcare delivery quality and improve patient outcomes, moving healthcare towards targeted, efficient, and personalized treatments.[57]

Genetic Profiling and High-Throughput Sequencing

Foundation of Precision Medicine: Precision medicine is built on understanding each patient's unique genetic makeup and the precise genomic variations that affect health and disease.[2] Genetic profiling, enabled by high-throughput sequencing technology, is essential for personalized healthcare. These advancements allow us to decode the genetic code with unprecedented speed and accuracy.[60]

The Human Genome Project and Beyond: The Human Genome Project marked the beginning of our exploration into the human genetic code. Since then, developments in high-throughput sequencing, also known as next-generation sequencing (NGS), have surpassed the project's completion. These advancements enable rapid and cost-effective whole-genome sequencing.[61]

DNA Sequencing Technologies: Various DNA sequencing technologies drive genetic profiling. Techniques such as Sanger sequencing, Illumina, and Oxford Nanopore offer distinct advantages and applications in precision medicine.[61]

The Omics Revolution: Genetic profiling extends beyond genomics to include other "omics" fields like transcriptomics, proteomics, and metabolomics. These disciplines provide a comprehensive view of an individual's biological landscape, revealing molecular interactions and pathways.[61]

Clinical and Research Applications: Genetic profiling has numerous applications in clinical and research settings. It guides clinical decisions in cancer diagnosis and treatment, prenatal testing, and the identification of rare diseases. Additionally, it advances biomedical research, enhancing our understanding of disease mechanisms and drug development.[61]

Challenges and Considerations: Despite its potential, genetic profiling faces challenges, including ethical considerations, data privacy protection, and the need for robust bioinformatics tools. Proper analysis of genetic data is critical to addressing these issues.[61]

Future Frontiers: The field of genetic profiling and high-throughput sequencing continues to evolve. Emerging technologies like single-cell sequencing and long-read

sequencing promise to deepen our understanding of genetic variation and disease, paving the way for the future of precision medicine.[61]

Technological Advancements

Technological advancements have significantly propelled the field of precision medicine, enabling more personalized and effective healthcare.[48] Next-generation sequencing (NGS) technologies have revolutionized genetic profiling, allowing for rapid and cost-effective analysis of entire genomes.[62] This has facilitated the identification of genetic variations that influence disease susceptibility and treatment responses.[14] Advancements in bioinformatics and data analytics have further enhanced our ability to interpret vast amounts of genetic data. These tools enable the integration of genetic data with other biological data, leading to more accurate diagnoses and targeted therapies.[41]

The integration of electronic health records (EHRs) with genetic data provides a comprehensive view of a patient's health history, genetic profile, and treatment responses.[63] This holistic approach helps healthcare providers make more informed and personalized treatment decisions.[48] Additionally, the development of CRISPR and other gene-editing technologies has opened new avenues for treating genetic disorders. These technologies allow for the precise targeting and modification of disease-causing genes, offering the potential for curative therapies.

Furthermore, the use of digital biomarkers and artificial intelligence (AI) is transforming precision medicine.[64] Digital biomarkers, derived from wearable devices and other digital health technologies, provide real-time health data that can be used to monitor and manage chronic diseases. AI algorithms can analyze complex datasets, identify patterns, and predict disease progression, enabling proactive and personalized healthcare.[65]

These technological innovations, combined with advancements in high-throughput sequencing, bioinformatics, and AI, are making it possible to predict, prevent, and treat diseases with unprecedented precision and efficacy.[48] The ongoing research and development in precision medicine hold the promise of improving patient outcomes, reducing healthcare costs, and ushering in a new era of personalized healthcare.[14]

Applications of precision medicine

Precision medicine has a wide range of applications that significantly enhance personalized healthcare.[48] In oncology, genetic profiling of tumors helps identify specific mutations, enabling the development of targeted therapies that improve treatment outcomes and minimize side effects.[19] In cardiovascular diseases, identifying genetic factors allows for tailored medication plans based on individual risk profiles.[66] Pharmacogenomics studies genetic variations affecting drug metabolism and response, helping to determine the most effective medications and dosages for each patient. Precision medicine is also

transformative in diagnosing and treating rare genetic disorders, with gene therapy offering potential cures. In neurological disorders, personalized treatment plans are developed based on genetic information, reducing the frequency of conditions like epilepsy.[67] Additionally, it plays a crucial role in infectious diseases by identifying genetic variations that influence susceptibility and response to treatments.[68] Prenatal and new born screening benefit from genetic testing to identify potential genetic disorders early. Autoimmune diseases, mental health conditions, and preventive medicine also see significant advancements through precision medicine, leading to more effective treatments, minimized side effects, and proactive healthcare approaches.[49] These applications showcase the transformative potential of precision medicine in improving patient outcomes and advancing personalized healthcare.[48]

Precision medicine in oncology:

Precision medicine in oncology, also known as personalized oncology or targeted oncology, is a medical approach that tailors cancer treatment to individual patients based on their unique genetic, molecular, and environmental profiles.[19] In the context of cancer, precision medicine typically involves examining alterations in specific genes or proteins within a patient's cancer cells to determine how these changes might influence their care, including treatment options.

Gene Changes and Cancer:

All cancers arise from gene changes.[69] Cancer cells are abnormal versions of normal cells, resulting from genetic alterations that transform a normal cell into a cancerous one. For instance, genes that typically prevent cells from growing uncontrollably might be turned off, or genes that promote cell growth and division might be permanently activated.[70]

Cancer development requires multiple gene changes within a cell. Although we don't yet know all the genes and mutations involved in cancer development, we do know some that can be tested for.

Sometimes, an abnormal gene increases a person's likelihood of developing a specific cancer. If they already have cancer, a particular gene change might affect their prognosis (outlook), making it better or worse compared to someone with the same cancer who doesn't have that gene change.

In certain cancer patients, having a specific gene change in their cancer cells might determine whether their cancer will (or will not) respond well to a particular treatment.[19] Typically, cancer patients receive the same treatment as others with the same cancer type. However, the gene changes in their cancer cells can vary, causing different responses to the same drug.[19] For some cancer types, doctors can now test for gene changes to determine if a patient's cancer will respond better to one drug over another.[71]

Precision medicine in cancer care

Precision medicine is increasingly being utilized in cancer care to determine the most appropriate tests and treatments for specific cases. Doctors may use precision medicine to:

- Identify individuals at high risk for cancer and assist them in reducing their risk.

- Detect certain cancers at an early stage.

- Accurately diagnose specific types of cancer.

- Select the most effective cancer treatment options.

- Assess the effectiveness of a treatment.

Cancer risk and prevention

Precision medicine is sometimes utilized for individuals with a higher likelihood of developing certain types of cancer. For instance, someone might discover a history of cancer in their family or a doctor might observe a recurring pattern. In such cases, the individual could consult with a certified genetic counselor and consider undergoing genetic testing. These tests can identify inherited genetic changes that increase the risk of specific cancers. If such risks are detected, doctors might recommend earlier or more frequent screenings, additional tests for early detection, medications, or lifestyle changes to help reduce the likelihood of cancer.[71]

Cancer diagnosis

For certain types of cancer, tests may be conducted on cancer cells to detect changes in specific genes or proteins resulting from these changes. Such testing provides valuable insights into the cancer, including its growth and spread. These tests are known by various terms, such as:

- Biomarker testing

- Tumor testing, also called tumor genetic testing, tumor marker testing, or tumor subtyping

- Genomic testing, which includes genomic profiling or genome sequencing

- Molecular testing, also referred to as molecular profiling or somatic testing

- Next-generation sequencing

Typically, testing involves analyzing a tumor sample obtained through biopsy or surgery. In some cases, samples of blood, saliva, or other bodily fluids might also be utilized for this purpose.[71]

Cancer treatment

For certain types of cancer, analyzing cancer cells for specific gene or protein changes (called biomarkers) can influence treatment choices. This approach is often referred to as "precision medicine."

Gene or protein changes can affect how a cancer responds to treatments, and these variations may differ even among individuals with the same type of cancer. For example, not all melanoma skin cancers share identical gene mutations, which means they may not respond to treatments in the same way.

Pharmacogenomic testing is one method doctors use to understand how gene or protein changes might affect a cancer's response to treatment. This testing provides insights into how a person's body metabolizes, absorbs, and utilizes treatment drugs.

Before beginning treatment, doctors can perform tests on cancer cells to identify gene and protein changes. This helps them determine the most effective treatments and avoid those that may not work.[71]

The two main types of treatments often used in precision medicine are:

- Targeted drug therapy – drugs designed to specifically target certain features of cancer cells.

- Immunotherapy – medications that enhance the body's immune system to fight the cancer.

Significant Aspects of precision oncology

Genetic Profiling:

Precision medicine involves analyzing the genetic mutations and molecular features of a patient's tumor. This information helps identify specific targets for treatment, allowing for the development of therapies that directly address the genetic abnormalities driving the cancer.[19]

Targeted Therapies:

Unlike traditional treatments like chemotherapy and radiation, which can affect both cancerous and healthy cells, targeted therapies focus on specific molecules involved in cancer growth and progression.[72] Examples include drugs that target the HER2 protein in breast cancer or the BRAF mutation in melanoma.

Biomarker Identification:

Biomarkers are biological molecules that indicate the presence or progression of a disease. In oncology, biomarkers can help predict how a patient will respond to a particular treatment, enabling more personalized and effective therapy plans.[73]

Molecular Subtyping:

Researchers are now able to classify cancers into more precise subtypes based on their molecular fingerprints. This allows for a more accurate diagnosis and the selection of treatments that are most likely to be effective for each specific subtype.

Clinical Applications:

Precision medicine is particularly useful when standard treatments fail. By sequencing the tumor's genome, doctors

can identify genetic mutations that may be contributing to treatment resistance and adjust the therapy accordingly.[19]

Preventive Measures:

Precision medicine also plays a role in cancer prevention. For individuals with a family history of cancer, genetic testing can identify inherited mutations that increase cancer risk. This information can guide early screening and preventive measures.[74]

The Challenges of Personalized Cancer Medicine

Personalized cancer medicine, while highly promising, faces several significant challenges that impact its accessibility and implementation.[19] One major challenge is tumor heterogeneity, as cancers are not uniform, and tumors within the same patient can exhibit varying genetic and molecular characteristics.[75] This diversity can lead to treatment resistance and recurrence. Additionally, cancer cells can develop resistance to targeted therapies, necessitating continuous adaptation of treatment strategies. The high costs associated with personalized therapies, including genetic testing and targeted drugs, pose another barrier, potentially limiting access for many patients.[76] Limited accessibility is further compounded by the fact that not all healthcare facilities are equipped to provide personalized cancer care. Moreover, lack of insurance coverage for such treatments creates an additional financial obstacle. Data management and interpretation represent another critical challenge.[2] Personalized medicine relies on analyzing vast and complex genomic and other data, requiring specialized expertise, robust infrastructure, and skilled personnel. Challenges such as storing, analyzing, and integrating data from various sources, including clinical records and genomic data, can be time-consuming and technically demanding.[77] Ethical and legal concerns also play a significant role. Collecting and analyzing genetic data raises privacy and confidentiality issues, while protecting sensitive patient data from unauthorized access remains paramount. Additionally, evolving regulatory frameworks for personalized medicine may delay the development and implementation of new therapies.[78] Concerns about potential discrimination against individuals with certain genetic predispositions or those undergoing personalized testing further complicate matters. Other obstacles include a shortage of healthcare professionals with the expertise to manage and interpret the complex data associated with personalized medicine. Both physician resistance and patient unawareness may hinder its adoption due to a lack of understanding or experience.[19] In developing nations, the limited availability of novel therapies and diagnostics exacerbates disparities in cancer care.[79] Moreover, rigorous clinical trials are needed to validate the efficacy and safety of personalized therapies, while challenges in obtaining tumor biopsies can delay treatment initiation.[80]

CONCLUSION

The convergence of technological advancements and pharmacogenomics has revolutionized the field of drug development, particularly in oncology.[19] This review has highlighted the transformative impact of technologies on the drug development process. Furthermore, the integration of pharmacogenomics into drug development has enabled personalized, targeted, and safer cancer treatments.

As we move forward, it is essential to address the challenges associated with the adoption of these technologies. Ensuring equitable access to genetic testing, protecting patient data, and promoting diversity in clinical trials are critical steps towards realizing the full potential of pharmacogenomics and precision medicine.

The future of drug development holds tremendous promise, with the potential for more effective, efficient, and personalized treatments.[14] By continuing to harness the power of technological innovation and pharmacogenomics, we can improve patient outcomes, enhance quality of life, and transform the landscape of cancer treatment.

Ultimately, this review aims to contribute to the ongoing dialogue on the intersection of technology and pharmacogenomics in drug development, highlighting the vast opportunities and challenges that lie ahead. By fostering collaboration, driving innovation, and promoting responsible adoption, we can unlock the full potential of these technologies and create a brighter future for patients worldwide.

REFERENCES

1. US National Library of Medicine. Pharmacogenomics: A primer for clinicians. Genetics in Medicine.2020;22(5):831-838. doi: 10.1038/s41436-020-0759-1

2. National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. National Academies Press.2011. DOI: 10.17226/13284

3. Mak, IW, Evaniew N. The Role of Artificial Intelligence in Drug Development. Journal of Clinical and Translational Research.2018;4(2): 53–56.

4. Altman R. B. Pharmacogenomics: A Key Component of Personalized Medicine. Journal of Clinical Pharmacology.2018; 58(Suppl 10):S3–S9. doi: 10.1002/jcph.1144

5. Roberts MC, Kennedy AE, Chambers DA, Khoury MJ. The current state of implementation science in genomic medicine: opportunities for improvement. Genetics in Medicine.2017;19(8):835–843. doi: 10.1038/gim.2016.210

6. Manolio, TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Rehm, HL. Bedside back to bench: Building bridges between basic and clinical genomic research.Cell.2019;179(4):771–774. doi: 10.1016/j.cell.2019.10.001

7. orgensen JT. The impact of technological advancements on drug development. Journal of Translational Medicine. 2019; 17(1): 1-8. doi: 10.1186/s12967-019-1832-0

8. DiMasi, JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016; 47: 20-33. doi: 10.1016/j.jhealeco.2016.01.012

9. Lamberti MJ, Wilkinson M. The challenges of clinical trial recruitment. Applied Clinical Trials.2018;27(10): 1-5.

10. Mak, IW, Evaniew N.The Role of Artificial Intelligence in Drug Development. Journal of Clinical and Translational Research.2018;4(2): 53-56.

11. Weinshilboum RM, Wang L. Pharmacogenomics: A new approach to individualized medicine. Journal of Clinical Pharmacology.2017; 57(Suppl 10):S3-S9. doi: 10.1002/jcph.944

12. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. Journal of the American Medical Association.2001; 285(5): 540-544. doi: 10.1001/jama.285.5.540

13. Bufill E, Barez G. Digital health technologies for precision medicine. Journal of Translational Medicine.2018; 16(1): 1-9. doi: 10.1186/s12967-018-1393-8

14. Collins FS, Varmus H. A new initiative on precision medicine. New England Journal of Medicine.2015; 372(9): 793–795. doi: 10.1056/NEJMp1500445

15. US National Library of Medicine. Pharmacogenomics: A primer for clinicians. Genetics in Medicine.2020; 22(5): 831–838. doi: 10.1038/s41436-020-0759-1

16. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature.2015; 526(7573): 343-350. doi: 10.1038/nature15519

17. Dancey, JE, Chen HX. Pharmacogenomics in cancer therapy: A review. Journal of Clinical Oncology.2017; 35(22): 2511–2518. doi: 10.1200/JCO.2017.72.2269

18. Kim J, Lee J. Pharmacogenomics and precision medicine in oncology. Journal of Precision Medicine.2020; 1(1): 1-12.

19. National Cancer Institute. Precision Medicine in Cancer Treatment. 2020. https://www.cancer.gov/research/areas/treatment/nci-precision-medicine-infographic

20. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. British Journal of Pharmacology.2011;162(6): 1239-1249. doi: 10.1111/j.1476-5381.2010.01127.x

21. Lavecchia A, Cerchia L. High-throughput screening and rational drug design in the discovery of new therapeutics. Journal of Medicinal Chemistry.2017; 60(11): 4497-4512. doi: 10.1021/acs.jmedchem.7b00173

22. Olson H, Betton G, Robinson D, Thomas , Monro A, Kolaja G, Walker T. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology.2000;32(1): 56-67. doi: 10.1006/rtph.2000.1395

23. Pocock SJ. Clinical trials: A practical approach. Wiley-Blackwell;2013.

24. Food and Drug Administration. (2020). New Drug Application (NDA). https://www.fda.gov/drugs/types-applications/new-drug-application-nda

25. Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. New England Journal of Medicine.2003; 348(6): 538-549. doi: 10.1056/NEJMra020526

26. Relling MV, Giacomini KM. Pharmacogenomics and the future of medicine. Journal of Clinical Pharmacology.2017;57(Suppl 10): S10-S16. doi: 10.1002/jcph.944

27. International HapMap Consortium. A haplotype map of the human genome. Nature.2005; 437(7063):1299-1320. doi: 10.1038/nature04226

28. Kalow W, Meyer UA. Pharmacogenetics. Marcel Dekker;2001

29. Crews KR, Hicks JK. Pharmacogenomics: A key component of precision medicine. Journal of Clinical and Translational Research.2017; 3(2):53-56.

30. Weinshilboum RM, Wang L.Pharmacogenomics: Precision medicine and drug response. Mayo Clinic Proceedings.2017;92(11):1711–1722. doi: 10.1016/j.mayocp.2017.09.001

31. Lesko LJ, Zineh I. Pharmacogenomics and personalized medicine: Implementation of pharmacogenetic principles into clinical practice. Journal of Clinical Pharmacology.2010;50(12): 1471-1476. doi: 10.1177/0091270010382591

32. US Food and Drug Administration. (2020). Guidance for Industry: Pharmacogenomic Data Submissions. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions

33. US Food and Drug Administration. (2020). Guidance for Industry: Adaptive Designs for Clinical Trials of Drugs and Biologics. http://fda.gov/media/78495/download

34. Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Pharmacogenomics.2004; 5(6): 771-784. doi: 10.1517/14622416.5.6.771

35. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pharmacogenomics;2020.

36. TP Aneesh, M Sonal Sekhar, Jose, Asha, Chandran, Lekshmi, Zachariah, Subin Mary. Pharmacogenomics: The right drug to the right person. Journal of Clinical and Medical Research.2009; 1(4): 191-194. doi: 10.4021/jocmr2009.08.1255

37. Pritchard CC, Cheng HH. Omics technologies and their application to precision oncology. Molecular Oncology.2017; 11(3): 237-244. doi: 10.1002/1878-0261.12033

38. Hopkins AL, Groom CR. The druggable genome. Nature Reviews Drug Discovery.2002; 1(9): 727-730. doi: 10.1038/nrd892

39. de Bono JS, et al. Phase I/II trial of the nicotinamide phosphoribosyl transferase inhibitor, NAD+, in patients with refractory prostate cancer. Journal of Clinical Oncology.2011; 29(2): 179-185. doi: 10.1200/JCO.2010.32.3690

40. Sarker MA, Workman P. Pharmacogenomics in preclinical drug development. Journal of Pharmacology and Experimental Therapeutics.2018; 366(2):241-253. doi: 10.1124/jpet.117.247804

41. Ginsburg GS, Willard HF. Genomic and precision medicine: Foundations, applications, and future directions. Elsevier;2017.

42. Steinhubl SR, Topol EJ. Digital medicine, on its way to being just plain medicine. NPJ Digital Medicine.2015; 1:15006. doi: 10.1038/npjdigitalmed.2015.6

43. Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. American Journal of Preventive Medicine.2016; 50(3):398-401. doi: 10.1016/j.amepre.2015.08.031

44. Cui, J., et al. Pharmacogenomics of rheumatoid arthritis: A systematic review. Journal of Rheumatology.2018;45(5): 555-564. doi: 10.3899/jrheum.171055

45. Hamburg MA, Collins FS. The path to personalized medicine. New England Journal of Medicine.2010; 363(4):301-304. doi: 10.1056/NEJMp1006304

46. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. New England Journal of Medicine.2014; 371(12): 1170-1172. doi: 10.1056/NEJMp1404776

47. Sibille E, Lewis DA. Precision medicine in psychiatry: From scissors to molecular mechanisms. Journal of Clinical Psychopharmacology.2018; 38(5): 448-455. doi: 10.1097/JCP.0000000000000941

48. National Academy of Medicine. (2016). Precision Medicine: An Action Agenda for the Future.

49. National Institutes of Health. (2020). Precision Medicine Initiative.

50. Abedon ST, et al. Bacteriophage therapy: A review of the treatment of bacterial infections. Journal of Medical Microbiology.2017; 66(11):1511-1523. doi: 10.1099/jmm.0.000623

51. Sarker SA, et al. Oral phage therapy of acute bacterial diarrhea in children. Journal of Medical Virology.2017; 89(5):774-782. doi: 10.1002/jmv.24737. PMID: 28150348.

52. US Food and Drug Administration. (2020). Bacteriophage Therapy. https://www.fda.gov/media/159400/download

53. American Cancer Society. (2020). Understanding Your Cancer Diagnosis. https://www.cancer.org/cancer/understanding-cancer.html

54. Marsh S, McLeod H L. Pharmacogenomics: From bedside to clinical practice. Human Molecular Genetics.2007; 16(2):R147-R153. doi: 10.1093/hmg/ddm243. PMID: 17913757.

55. Jameson J L, Longo D L. Precision medicine: Personalized, problematic, and promising. New England Journal of Medicine.2015; 372(23):2229-2234. doi: 10.1056/NEJMra1410423.

56. National Cancer Institute. (2020). Personalized Medicine

57. US Food and Drug Administration. (2020). Paving the Way for Personalized Medicine. https://www.agemed.org/Portals/0/PDF/FDA%20-%20Paving%20the%20Way%20for%20Personalized%20medicine.pdf

58. President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine.2008

59. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory. Biotechnology Journal.2012; 7(8):1020-1028. doi: 10.1002/biot.201200085. PMID: 22851304.

60. Metzker ML. Sequencing technologies — the next generation. Nature Reviews Genetics.2010;11(1):31-46. doi: 10.1038/nrg2626. PMID: 19997069.

61. Singla A. Precision Medicine: Tailoring Treatment to Individual Genetic Profiles. Shodh Sagar Journal for Medical Research Advancement.2024;1(1):27-37. DOI: https://doi.org/10.36676/ssjmra.v1.i1.04

62. Mardis ER. Next-generation sequencing: Challenges and opportunities for precision medicine. Nature Reviews Genetics.2013;14(10): 635-644. doi: 10.1038/nrg3557.

63. Mandl KD, Kohane IS. Time for a patient-driven health information ecosystem. New England Journal of Medicine.2016;374(3): 205-208. doi: 10.1056/NEJMp1513149.

64. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine.2019; 25(1): 44-56. doi: 10.1038/s41591-018-0307-4.

65. Rajkomar A, et al. Machine learning in medicine. New England Journal of Medicine.2019; 380(14): 1347-1358. doi: 10.1056/NEJMra1814259.

66. American Heart Association. (2017). Precision Medicine in Cardiovascular Disease. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.117.310782

67. National Institute of Neurological Disorders and Stroke. (2020). Genetics and Epilepsy. https://www.ninds.nih.gov/

68. National Institute of Allergy and Infectious Diseases. (2020). Genomics and Infectious Diseases. https://www.niaid.nih.gov/

69. National Cancer Institute. (2020). The Genetics of Cancer. https://www.cancer.gov/about-cancer/causes-prevention/genetics

70. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature Medicine.2004; 10(8): 789-799. doi: 10.1038/nm1087

71. American Cancer Society. Precision or Personalized medicine.

doi: https://www.cancer.org/cancer/managing-cancer/treatment-types/precision-medicine.html

72. American Cancer Society. (2020). Targeted Therapy. https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy.html

73. National Cancer Institute. (2020). Biomarkers and Cancer. https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment

74. National Cancer Institute. (2020). Cancer Prevention and Control. https://www.cancer.gov/about-cancer/causes-prevention/patient-prevention-overview-pdq

75. Swanton C. Intratumor heterogeneity: Evolution through space and time. Cancer Research.2012; 72(19): 4875-4882. doi: 10.1158/0008-5472.

76. Kantarjian HM, Fojo T. The cost of new drugs for cancer. Journal of Clinical Oncology.2012; 30(22): 2790-2791. doi: 10.1200/JCO.2012.42.2573.

77. National Institutes of Health. (2020). Data Sharing and Precision Medicine. https://www.healthaffairs.org/doi/10.1377/hlthaff.2017.1558

78. US Food and Drug Administration. (2020). Precision Medicine. https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine

79. World Health Organization. (2020). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

80. National Cancer Institute. (2020). Clinical Trials and Precision Medicine. https://link.springer.com/article/10.1186/s13073-022-01102-